앱클론(주)
| KRW bn | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.7 | 0.4 | 1.1 | 1.6 | 1.6 | 0.4 | 1.7 | 1.8 |
| Operating income | -3.2 | -5.8 | -3.3 | -3.5 | -5.0 | -3.1 | -6.3 | -3.9 |
| Net income | -3.3 | -6.0 | -3.5 | -3.5 | -5.1 | -2.8 | -6.1 | -3.8 |
| Cash from operations | -3.0 | -6.4 | -3.0 | -2.2 | -2.2 | -3.2 | -6.0 | -4.5 |
| Free cash flow | -3.0 | -6.9 | -3.0 | -2.2 | -2.4 | -3.2 | -6.1 | -4.5 |
| KRW bn | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 2.9 | 2.3 | 4.7 |
| Operating income | -11.6 | -15.6 | -17.6 |
| Net income | -12.9 | -16.3 | -17.9 |
| Cash from operations | -9.5 | -14.4 | -13.8 |
| Free cash flow | -9.5 | -14.6 | -14.4 |
| Gross margin | 12.0% |
| ROA | -36.3% |
| Liabilities / equity | 0.19x |
| Current ratio | 4.13x |
| FCF margin | -294.0% |
| CFO / net income | 0.90x |
| Net debt (KRW) | -24.7 bn |
| Filing | Form | ||
|---|---|---|---|
| Fri 13 Nov 2026 | |||
| Quarterly Report — 2026.09 | 10-Q | ||
| Fri 30 Oct 2026 | |||
| Material Information for Investment Decisions 투자판단관련주요경영사항 (TIGIT 표적 항체신약 후보물질 도출 공동연구개발 및 기술이전의 건) | 8-K | ||
| [Amendment] Single Sales / Supply Contract — Voluntary | 8-K/A | ||